Turkish Version of the Arthritis Self-Efficacy Scale-8 (T-ASES-8)

May 5, 2025 updated by: Bezmialem Vakif University

Cross-cultural Adaptation and Validation of a Turkish Version of the Arthritis Self-Efficacy Scale-8 (ASES-8) for Patients With Knee Osteoarthritis

Self-efficacy is a psychosocial construct that reflects an individual's confidence in their ability to perform specific tasks, focusing more on one's belief in their abilities than on actual performance. This concept is especially important in knee osteoarthritis (KOA) management, as it can significantly influence overall health and treatment outcomes, and it is considered a modifiable trait.

KOA is one of the most common musculoskeletal disorders worldwide, substantially impacting quality of life due to symptoms such as limited mobility, chronic pain, and joint stiffness. These symptoms can hinder daily activities and potentially lead to social isolation. In patients with KOA, a strong sense of self-efficacy can improve symptom management and increase participation in physical activities. Research indicates that patients with higher self-efficacy are more likely to engage actively in rehabilitation programs and achieve their treatment goals. Consequently, various self-efficacy measurement tools have been developed to better understand patients' perceptions of their condition and the extent of their disability, which in turn aids in formulating strategies to enhance self-efficacy and optimize treatment responses.

The Arthritis Self-Efficacy Scale (ASES) is widely used to assess self-efficacy in managing pain, physical functions, and other symptoms associated with arthritis. Compared to other self-efficacy instruments, the ASES has a longstanding history and is particularly applicable to KOA. Its validity and reliability have been confirmed through several studies. Initially developed as a 20-item scale with three subscales evaluating physical function, pain, and other symptoms, a shorter version-the eight-item ASES-8-was later created. This abbreviated version includes two items from the pain subscale, four items from the other symptoms subscale, and two additional items addressing fatigue and pain prevention during daily activities. Each item is rated on a scale from 1 (very uncertain) to 10 (very certain), indicating the patient's level of confidence in managing their condition.

Although the ASES-8 has been validated in several languages, it has not yet been translated into Turkish or culturally adapted for Turkish patients with KOA. Cross-cultural adaptation of patient-reported outcome measures (PROMs) requires rigorous methodologies to ensure both accurate translation and the preservation of content validity. Reliable, valid, and culturally sensitive instruments are essential for developing effective interventions for Turkish-speaking patients with KOA. Therefore, this study aims to translate and cross-culturally adapt the ASES-8 into Turkish and evaluate the reliability and validity of the resulting instrument.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Turkey
    • Fatih
      • Istanbul, Fatih, Turkey, 34093
        • Bezmialem Vakif University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

This study targets adult patients aged 18 years and older who have been diagnosed with knee osteoarthritis (KOA) based on the American College of Rheumatology (ACR) criteria. Participants must possess sufficient language proficiency to understand and complete the Turkish version of the ASES-8 scale and must be willing to provide informed consent. The study excludes individuals with health conditions that render them unsuitable for self-management programs, those with behavioral or cognitive impairments that could interfere with the assessment process, and patients with unstable angina or uncontrolled heart failure.

Description

Inclusion Criteria:

  • Age ≥ 18 years
  • Diagnosis of knee osteoarthritis (KOA) according to the American College of Rheumatology (ACR) criteria
  • Sufficient language skills to understand and complete the scale
  • Provision of informed consent

Exclusion Criteria:

  • Health conditions unsuitable for a self-management program
  • Behavioral or cognitive issues that could hinder the assessment process
  • Unstable angina or uncontrolled heart failure

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Patients with Knee Osteoarthritis (KOA)

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Construct Validity and Reliability of the Turkish ASES-8
Time Frame: 1 month

Self-Efficacy in Knee Osteoarthritis (KOA) Management

The primary outcome of our study is to assess the level of self-efficacy in managing KOA among Turkish-speaking patients. This is operationalized through the culturally adapted version of the Arthritis Self-Efficacy Scale-8 item version (ASES-8).

Key Features of the Primary Outcome Measure:

Instrument Overview:

The ASES-8 is designed to evaluate the patient's confidence in managing key symptoms associated with KOA-including pain, functional limitations, fatigue, and pain prevention during daily activities. Unlike performance-based tests, this instrument focuses on patients' beliefs about their own abilities to manage these aspects, which is crucial for effective self-management.

Measurement Details:

Item Structure: The ASES-8 consists of eight items. Two items are derived from the pain subscale, four from the other symptoms subscale, and two additional items address fatigue and preventive strategies against pain during daily ac
1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Bezmialem Vakif University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 15, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
April 25, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 1, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 7, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 15, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 16, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 7, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 5, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2023/211

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings